Synonyms: AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg
romosozumab is an approved drug (Japan, FDA and EMA (2019))
Compound class:
Antibody
Comment: Romosozumab is a humanised anti-sclerostin monoclonal antibody that was developed by Amgen and UCB for the treatment of osteoporosis [4-5]. Amgen holds patent protection claiming the polypeptide composition of romosozumab in the US and the EU (expected expiry in 2026).
|
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. Japan (2019) | FDA (2019) | EMA (2019) |
International Nonproprietary Names ![]() |
|
INN number | INN |
9533 | romosozumab |
Synonyms ![]() |
AMG-785 | CDP-7851 | Evenity® | romosozumab-aqqg |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 404 |
Other databases | |
GtoPdb PubChem SID | 249565772 |
Search PubMed clinical trials | romosozumab |
Search PubMed titles | romosozumab |
Search PubMed titles/abstracts | romosozumab |
Wikipedia | Romosozumab |